New oxygen-based test could prevent kidney damage from blood transfusions in ICU

NCT ID NCT06102590

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a measure called oxygen extraction ratio (O2ER) to guide blood transfusions can reduce kidney injury in critically ill patients. About 324 ICU patients with low hemoglobin will be randomly assigned to receive transfusions based on O2ER levels or standard guidelines. The goal is to see if this personalized approach improves outcomes like kidney function and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
red blood cell transfusion guided by oxygen extraction ratio
What this could lead to
If successful, this could lead to a safer, more personalized way to decide when ICU patients need a blood transfusion, potentially reducing kidney damage.
What could go wrong
This is a mid-sized trial (324 participants) and the approach is still experimental. The benefit may be small or not apply to all critically ill patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD TRANSFUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anestesia e Rianimazione Cardio-Toraco-Vascolare

    RECRUITING

    Siena, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Erasme

    NOT_YET_RECRUITING

    Brussels, Belgium

    Contact

  • Università di Ferrara

    RECRUITING

    Ferrara, Ferrara, 44121, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • Università di Perugia

    RECRUITING

    Perugia, Italy, 06121, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.